Isotope maker Nordion’s profit jumps on sale of unit

(Reuters) – Nordion Inc, a provider of isotopes used in medical imaging, reported a big jump in quarterly profit on Thursday after recording an after-tax gain of about $182 million on the sale of its targeted therapies business. The Canadian company’s results beat market expectations and its shares climbed 1.8 percent to C$8.39 on the Toronto Stock Exchange. Nordion completed the $200-million sale of its targeted therapies division to British health care company BTG Plc in July. The business’s sole product was the liver cancer therapy TheraSphere. …